Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of tiragolumab plus atezolizumab versus atezolizumab alone in PD-L1-positive metastatic or recurrent cervical cancer
2019-004895-21Phase 2Unknown
- Sponsor
- Roche
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in Cervical Cancer (CC) comparing tiragolumab + atezolizumab with atezolizumab monotherapy (2 arms). Primary endpoint: Objective response rate. Status: unknown.
02
Drugs
tiragolumabatezolizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on 2019-004895-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004895-21.